Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer
Work
Year: 2021
Type: article
Abstract: Ensartinib, an oral tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system efficacy for patients with ALK-positive non-small cell lung cancer (NSC... more
Source: JAMA Oncology
Institutions Vanderbilt University, Vanderbilt-Ingram Cancer Center, AstraZeneca (United States), Peking University Cancer Hospital, Peking University +21 more
Cites: 32
Cited by: 164
Related to: 10
FWCI: 25.35
Citation percentile (by year/subfield): 100
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid